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Abstract
Background: Patients with advanced microsatellite unstable colorectal cancers do not show a survival benefit from 5-
fluorouracil (5-FU)-based chemotherapy. We and others have shown that the DNA mismatch repair (MMR) complex hMutSa
binds 5-FU incorporated into DNA. Although hMutSß is known to interact with interstrand crosslinks (ICLs) induced by drugs
such as cisplatin and psoralen, it has not been demonstrated to interact with 5-FU incorporated into DNA. Our aim was to
examine if hMutSß plays a role in 5-FU recognition.
Methods: We compared the normalized growth of 5-FU treated cells containing either or both mismatch repair complexes
using MTT and clonogenic assays. We utilized oligonucleotides containing 5-FU and purified baculovirus-synthesized
hMutSa and hMutSß in electromobility shift assays (EMSA) and further analyzed binding using surface plasmon resonance.
Results: MTT and clonogenic assays after 5-FU treatment demonstrated the most cytotoxicity in cells with both hMutSa and
hMutSß, intermediate cytotoxicity in cells with hMutSa alone, and the least cytotoxicity in cells with hMutSß alone, hMutSß
binds 5-FU-modified DNA, but its relative binding is less than the binding of 5-FU-modified DNA by hMutSa.
Conclusion: Cytotoxicity induced by 5-FU is dependent on intact DNA MMR, with relative cell death correlating directly with
hMutSa and/or hMutSß 5-FU binding ability (hMutSa.hMutSß). The MMR complexes provide a hierarchical
chemosensitivity for 5-FU cell death, and may have implications for treatment of patients with certain MMR-deficient
tumors.
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Introduction
The fluoropyrimidine 5-fluorouracil (5-FU) is the cornerstone
for chemotherapy in patients with advanced stage colorectal
cancer [1]. In addition to stage, the DNA mismatch repair (MMR)
status of a patient’s tumor appears to predict a survival response to
5-FU [2]. Patients with Lynch syndrome (germline mutation in
MMR gene) or patients with sporadic microsatellite unstable (MSI)
cancers (hypermethylation of the MMR gene hMLH1) do not show
a survival advantage with systemic 5-FU therapy [3,4,5,6],
whereas patients with MMR-proficient tumors improve their
survival. These observations correlate with 5-FU treatment of
MMR-deficient cells in that these cells are resistant to 5-FU
[7,8,9], and continue to survive in its presence.
The DNA MMR system plays an important role in maintaining
DNA fidelity after DNA synthesis for cell replication. DNA MMR
has two recognition complexes for DNA alterations. hMutSa,a
heterodimer of the MMR proteins hMSH2 and hMSH6,
recognizes base-base and insertion/deletion (I/D) loops less than
two nucleotides [10], whereas ID loops more than 2 nucleotides
are recognized by hMutSß, an hMSH2-hMSH3 heterodimer
[11,12,13,14,15,16,17,18]. Notably, hMutSa not only recognizes a
nucleotide mispair, but can also recognize altered nucleotides that
are intercalated or formed with chemotherapy, such as the adduct
O
6-methylguainine, and intrastrand crosslinking induced by
cisplatin [19]. We and others have further demonstrated that 5-
FU incorporated into DNA is recognized by hMutSa [9,20,21].
Systemic 5-FU therapy leads to incorporation into all forms of
RNA, but by its action upon thymidylate synthetase (TS), 5-FU
after conversion to a deoxyribonucleic acid serves as a substrate for
DNA synthesis with cell depletion of TTPs. It has been estimated
that as much as 10% of cellular 5-FU is incorporated into DNA
where MMR can recognize, bind, and signal cell death [7].
Isolation of 5-FU in DNA specifically triggered a DNA MMR-
dependent cell death [22]. In the absence of DNA MMR, these
events do not occur, and account for the cell resistance and lack of
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Because of some indications in the literature regarding hMSH3, a
component of hMutSß, in participating in the repair of psoralen
and platinum compounds [23,24], we wondered if hMutSß could
recognize 5-FU. Given that 5-FU incorporated into DNA would
best simulate a single mispair, we initially predicted that hMutSß
would not bind or recognize 5-FU, unlike hMutSa. The presence
of hMSH3, the DNA recognition component of hMutSß, is the
likely molecule that prevents the occurrence of elevated microsat-
ellite alterations at selected tetranucleotide repeats (EMAST) in
colorectal cancers, as reduced expression of hMSH3 has been
detected among these tumors [25,26]. EMAST (and hMSH3
deficiency) is associated with CRC progression, advanced staged
tumors, poor prognosis, and African American race [27]. hMutSß
has not been previously assessed for recognition of 5-FU
incorporated into DNA.
Here, we purified the hMutSß complex as a heterodimers of
hMSH3 and hMSH2 and examined its binding ability for 5-FU
that is incorporated into DNA. Overall, we herein show that 5-FU
cell toxicity correlates directly with relative hMutSa and/or
hMutSß binding ability.
Results
The level of 5-FU cytotoxicity depends upon the hMutSa
and hMutSß status of the cell
We performed two growth assays to identify if hMutSß had any
contribution towards 5FU cytotoxicity. By clonogenic assay, the
number of colonies in hMutSa/hMutSß double competent cells
was smaller than that in either hMutSa alone competent cells
(P,0.05) or hMutSß alone competent cells (P,0.05) (Fig. 1A).
The results of clonogenic assays were confirmed by MTT assay
(Fig. 1B). In addition, the results utilized by MTT assay showed
that hMutSa/hMutSß double competent cells had the lowest
survival rate (P,0.05), followed by intermediate survival in
hMutSa alone positive cells (P,0.05) and the best survival in
hMutSß alone positive cells (P,0.05) (Fig. 1B). To further clarify
the role of hMutSß for 5FU cytotoxicity, we transfected SW480
(MMR-proficient colorectal cancer cells) with an hMSH3 shRNA
expression plasmid (Fig. 1C). Knock down of hMSH3 reversed
some 5-FU-induced cell death over control cells by clonogenic
assay (Fig. 1D). These results indicate that not only hMutSa
triggers 5-FU cytotoxicity as reported previously [9,20,21], but
hMutSß also contributes to the 5-FU cytotoxicity. The contribu-
tion towards 5-FU cytotoxicity appears greatest when both
hMutSa and hMutSß are present, with both completes contrib-
uting a portion towards cell death.
Purified hMutSß recognizes and binds 5-FU-incorporated
into DNA, and exhibits ATP-induced dissociation
Based on the cell growth data that indicates a contribution of
hMutSß for 5-FU cytotoxicity, we investigated the hMutSß
recognition of 5-FU incorporated into DNA. We successfully
purified a stable recombinant hMutSß complex (Fig. 2A) similar
to our previously described approach for the hMutSa complex
[20]. We co-infected Sf9 cells with hMSH2 and hMSH3
baculoviral constructs, and extracted and purified the proteins as
a heterodimer utilizing two separate FPLC purification columns.
Coomassie blue staining verified hMutSß purification (Fig. 2A),
which we further confirmed was a heterodimer by immunopre-
cipitation of purified hMutSß with hMSH2 and hMSH3
antibodies (not shown). Utilizing the purified hMutSß for EMSA,
we examined hMutSß ability to bind perfect complementary
DNA, an AA insertion/deletion (I/D) loop, as well as 5-FU-
modified DNA. As shown in Fig. 2B, purified hMutSß
demonstrated little binding to complementary DNA, whereas
significantly more binding was observed with the AA I/D loop
(Fig. 2B). Interestingly, EMSA demonstrated that purified
hMutSß bound 5FdU-modified DNA (Fig. 2B, lane 8) but to a
lesser degree than hMutSß binds DNA containing the AA I/D
loop (Fig. 2B, lane 5). Controls without protein did not show the
hMutSß-DNA complex band. The addition of ATP causes
hMutSß to dissociate from DNA. We demonstrate that purified
hMutSß disassociates from DNA containing 5-FU as well as from
DNA containing the AA I/D loop when 4 mM ATP was added to
the hMutSß/DNA mixture (Fig. 2B, lanes 3, 6, and 9). This is
analogous to our observation for ATP-dependent dissociation of
hMutSa from DNA containing 5FdU [20].
Purified hMutSß dynamically binds 5-FU in DNA, but
hMutSa binds to 5-FU to greater extent than hMutSß
As we have already demonstrated the binding ability of hMutSa
[20] we further examined the dynamics of the binding and
dissociation between hMutSß and 5-FU incorporated into DNA to
understand the contribution of each of hMutSa and hMutSß for 5-
FU recognition. Utilizing the IAsys biosensor system [28], there is
essentially no binding of purified hMutSß on IAsys cuvettes
without any substrate. In contrast, hMutSß binds to complemen-
tary DNA to a low extent. The binding ability of purified hMutSß
for 5-FU incorporated into DNA was greater than for perfect
complementary DNA (,1.3-fold increased) but less than for DNA
containing the AA I/D loop, which was ,1.8-fold increased over
perfect complementary DNA (Fig. 3A). The addition of ATP
caused a rapid partial dissociation of hMutSß from all of the DNA
substrates and approached steady-state equilibrium 5 minutes
after ATP was added with dissociation from the G/C substrate
approaching equilibrium faster than dissociation from 5-FU or the
AA I/D loop (Fig. 3A). To assess the relative binding of hMutSa
and hMutSß, we compared affinity levels between hMutSa and
hMutSß upon the 5-FU-modified DNA utilizing IAsysh. MutSa
binds 5-FU at a greater extent than hMutSß (,2-Fold increase)
(Fig. 3B). Our observations demonstrate that hMutSa and
hMutSß have separate but also additive roles for recognition of
5-FU incorporated into DNA, which corresponds to the relative
cell toxicity triggered by 5-FU incorporated into DNA when the
MMR complexes are present.
Discussion
It has been recently demonstrated that hMSH3, the recognition
component of hMutSß, plays an important role in recognizing
DNA damage, particularly interstrand crosslinks [23,24]. Al-
though the importance of this component of hMutSß has been
recognized in furthering CRC progression, there is no data
regarding hMutSß contributions in executing 5-FU toxicity, a key
issue since all major therapy for CRC involves 5-FU. Our study
demonstrates (a) that 5-FU cytotoxicity depends on the hMutSa
and hMutSß status of cells, with the most cytotoxicity observed
when both hMutSa and hMutSß are present, intermediate 5-FU
cytotoxicity when hMutSa is retained but hMutSß is deficient, and
low 5-FU cytotoxicity when cells are hMutSa deficient but
hMutSß proficient, (b) that hMutSß recognizes 5-FU-containing
DNA, (c) and that the binding affinity of hMutSß is lower than
that of hMutSa, which directly correlates with 5-FU cytotoxicity.
This is the first study demonstrating an additive role for 5-FU
cytotoxicity for hMutSa and hMutSß.
Our data indicate that 5-FU cytotoxicity is more severe in cells
that retain both hMutSa and hMutSß than the cells that lack
Mismatch Repair and 5-Fluorouracil
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hMutSa recognition of 5-FU incorporated into DNA plays an
important role for 5-FU chemosensitivity [20]. It is somewhat
surprising that our EMSA results showed that a single base-pair of
5-FU incorporated into DNA is recognized by hMutSß in spite of
its general role for recognition of I/D loops greater than 2
molecules, and not single mispairs. This could be due to something
unique regarding 5-FU, such as its negative charge, or an atypical
or unrecognized role for hMutSß in recognizing altered nucleo-
tides. Takahashi et al. demonstrated that cells that lack hMSH3,a
component of hMutSß, are more sensitive to cysplatin and
oxaliplatin than hMSH3-proficient cells [24]. Interestingly, they
demonstrated that the difference of chemosensitivity between
hMSH3-deficient and hMSH3-proficient cells occurred indepen-
dently of hMLH1 status. In addition, it has been shown that
hMutSß recognizes ICLs induced by psoralen [23], and is not
Figure 1. Cell survival after 5-FU treatment is influenced by the hMutSa and hMutSß status. (A) Clonogenic assay of hMutSa and/or
hMutSß proficient cells in response to 5-FU. Cells were plated in media containing 0, 2.5, 5 mM 5FU and allowed to form colonies over 10 days. The
plates were then fixed with methanol and stained with 3% Giemsa, and viable colonies were counted. (B) MTT assay of the same cells as above, with
mean values shown with standard deviations. Each cell line was incubated with the 5 mM 5FU for 2.5 and 5 days. (C, D) SW480 were stably
transfected with an hMSH3 shRNA expression plasmid for hMSH3 knockdown, and stable hMSH3-deficient clones were utilized for clonogenic assay
in media containing 0, 2.5, 5 mM 5-FU and allowed to form colonies over 20 days (D). The plates were then fixed with methanol and stained with 3%
Giemsa, and viable colonies were counted. Western blotting with anti-hMSH3 antibody was performed to confirm the hMSH3 knockdown (C). Each
experiment was performed in triplicate, and the experiment replicated three independent times. *=P,0.05.
doi:10.1371/journal.pone.0028117.g001
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interact with nucleotide excision repair (NER) proteins, and
homologous recombination (HR) repair level for ICLs is also
dependent on hMutSß and not on hMutSa, which may suggest
that hMutSß may cooperate with the NER or HR proteins for
ICLs repair perhaps independently of traditional DNA MMR
[29]. It is possible that hMutSß recognition of 5-FU incorporated
into DNA might trigger MMR-independent repair mechanisms on
top of classical DNA MMR [8,9,30].
Our data indicates a direct relationship of MMR complex
affinity for binding and 5-FU cytotoxicity. Using surface plasmon
resonance (IAsys), we measured a 2- fold difference in binding
between hMutSa and hMutSß, with hMutSa having the greater
affinity for 5-FU within DNA. In addition, the results of IAsys and
cell growth assays suggest that hMutSa and hMutSß have additive
roles in triggering 5-FU cytotoxicity. Overall, our functional
observations of hMutSß in addition to hMutSa [20] for 5-FU
cytotoxicity suggest it important to understand a patient’s tumor
character and functional genotype.
A number of studies indicate that patients with advanced
colorectal cancer that DNA MMR-deficient do not derive a
survival benefit with systemic 5-FU chemotherapy. The majority
of these studies contained patients with somatic hypermethylation
of the hMLH1 promoter, rendering the tumor completely MMR-
deficient because for repair to occur after DNA synthesis, both
recognition of mismatch in the DNA by either hMutSa or hMutSß
and signaling for excision of the mismatch by a second
heterodimer, hMutLa (consisting of the MMR proteins hMLH1
and hPMS2), are essential. In contrast, partial MMR function
remains when either hMutSa (normal function of both hMutSß
and hMutLa) or hMutSß (normal function of hMutSa and
hMutLa) is lost. There are at least two scenarios for which
hMutSa and/or hMutSß function might be exploited for a partial
response to 5-FU. The first is Lynch syndrome patients with an
hMSH6 germline mutation (as opposed to hMLH1 or hMSH2
mutations, and there has not been any hMSH3 germline mutations
identified to date). These patients might demonstrate partial
response to 5-FU when compared to Lynch syndrome patients
with hMLH1 or hMSH2 germline mutations. The second is with
patients whose tumors show EMAST. Up to 60% of colon and
30% of rectal cancers have EMAST, and EMAST is associated
with loss of hMSH3 expression. Patients with EMAST tumors
might demonstrate a reduced 5-FU response compared to patients
with MSS tumors, and improved response when compared to
patients with hMLH1 hypermethylation in their tumors.
In conclusion, we demonstrated the hMutSß recognition of 5-
FU incorporated into DNA, and both hMutSa and hMutSß has
additive roles in triggering 5-FU cytotoxicity. Our data indicates
that the MMR complexes provide a hierarchical chemosensitivity
for 5-FU cell death. Our findings may have implication for specific
Lynch syndrome patients as well as specific CRC patients whose
tumors demonstrate EMAST. These groups of patients should be
studied for their response to 5-FU systemic therapy.
Materials and Methods
Cell Lines, Cell Culture and Transfection
The human colon cancer cell lines DLD1, HCT116+ch3,
HT29 and SW480 were obtained from American Type Culture
Collection (Rockville, MD) and maintained in growth medium
containing 10% fetal bovine serum (FBS). Of these cell lines,
DLD1 is defective for hMutSa (hMutSß competent),
HCT116+ch3 is deficient for hMutSß (hMutSa competent), and
SW480 and HT29 cells have been described proficient in and
stable at microsatellites (hMutSa and hMutSß competent). For
isolation of stable hMSH3-deficient clones, SW480 cells were
transfected with a retroviral vector that encodes shRNA to
hMSH3 (kind gift by the C. Richard Boland laboratory [24]) by
using FuGENEH6 (Roche, IN), and selection was done using both
400 mg/ml of G418 and 1 mg/ml of puromycin. After selection,
colonies were pooled and cultured for analysis. Stable cell lines
were confirmed by DNA sequencing.
Reagents
5-FU was obtained from Sigma Chemical Co. (St. Louis, MO)
and dissolved in Iscove’s modified Dulbecco’s medium at a stock
concentration of 1 mmol/L and maintained at 4uC.
Figure 2. Purification of hMSH3-hMSH2 heterodimer, and
binding of hMutSß to 5-FU incorporated within DNA. (A) Purity
of baculovirus-synthesized hMutSb on Coomassie blue staining of
electrophoresed protein extracts. Extracts from crude baculovirus-
synthesized proteins (left lane), and FPLC-purified baculovirus-synthe-
sized proteins (right lane) were electrophoresed on a 7.5% PAGE gel,
and stained with 0.1% Coomassie blue. Note the retention of 127 kD
and 105 kD protein bands in FPLC-purified extracts, which by Western
blotting corresponded to hMSH3 and hMSH2 proteins. (B) Electro-
mobility gel shift assays utilizing purified hMutSß and complementary
(lanes 1–3), AA I/D loop (lanes 4–6), and 5-FU-containing oligonucle-
otides (lanes 7–9). Radiolabeled oligonucleotides were incubated with
or without purified hMutSß in the presence or absence of 4 mM ATP.
Note the acquisition of an oligo-hMutSß band with the two adenines ID
loop (lane 5) or 5-FU-containing DNA (lane 8) when incubated with
purified hMutSß, and the dissolution of the complex with the addition
of ATP (lane 6, lane 9). Intensity of the band formed between 5-FU-
modified DNA and hMutSß was weaker than that of the AA I/D loop
formed with hMutSß.
doi:10.1371/journal.pone.0028117.g002
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28117Figure 3. Dynamics of binding and dissociation between hMutSß and 5-FU. (A) Biosensor analysis (surface plasmon resonance) of the
association (left curves) and ATP-induced dissociation (right curves) between hMutSß and AA I/D loop (curve a), 5-FU-containig DNA (curve b), or
complementary DNA (curve c). A dissociation buffer containing 4 mM ATP was added (arrow) after 5 minutes of association for dissolution
experiments. Note the initial rapid dissociation upon the addition of ATP, followed by a slower dissolution phase lasting more than 5 minutes to
reach steady state for the three DNA substrates. Controls (curves d and e) indicate the specificity of ATP’s effect when hMutSß is bound to a DNA
substrate compared to when the DNA substrate is absent. (B) Binding affinity of hMutSa (curves a) or hMutSß (curves b) to 5-FU-containing DNA.
hMutSa bound 5-FU DNA ,2-fold higher than hMutSß in the consecutive experiments.
doi:10.1371/journal.pone.0028117.g003
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Exponentially growing cells were trypsinized and washed twice
with PBS. Cells were then plated on 60615 mm Tissue Culture
Dish (Becton Dickinson Labware, NJ) in Iscove’s modified
Dulbecco’s medium supplemented with 10% FBS and containing
various concentrations of 5-FU (0, 2.5, and 5 mmol/L), then
incubated at 37uC and 5% CO2. After 10 days of growth, the
culture plates were washed with PBS, fixed with methanol for
15 minutes, and then rewashed with PBS. The colonies were
stained with 3% Giemsa (Sigma, St Louis, MO) for 15 minutes
and rinsed with water. Previously viable clonal colonies of at least
50 cells were counted. The relative surviving fraction for each cell
line was expressed as a ratio of the plating efficiency in treated
cultures to that observed in the controls.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
Exponentially growing cells were seeded onto 96-well plates and
grown for 1 day. Cells were treated with or without 5-FU at the
concentration of 5 mM. After 2.5 and 5 days later, 5 mg/ml MTT
(Sigma, St Louis, MO) in PBS was added and incubated for 3 h.
The absorbance was determined at 570 nm with a microplate
reader (Biorad).
Synthesis of 5-FU-containing oligonucleotides
We synthesized 38-mers in an oligonucleotide synthesizer (ABI,
Foster City, CA) at the UCSD Cancer Center Oligonucleotide
Synthesis Core for the experiments. For a negative control (i.e.
perfect complement), we made 59-TTTCTGACTTGGATAC-
CATCTATCTATCTATAAAATAT-39 and for a positive con-
trol, we made 59-TTTCTGACTTGGATACCATCTATC-
TATCTATAA-AA-AATAT-39 which differs from the perfect
complement at the 34th nucleotide (insertion of two adenines). To
synthesize the 5-FU-containing DNA, we utilized the phosphor-
amdite form of 5-fluorodeoxyuracil (5FdU) (Glenn Research,
Sterling, VA) to make 59-TTTCTGACTTGGATACCA-5FdU-
CTATCTATCTATAAAATAT-39. To complete the double-
stranded DNA molecule, the complementary sequence of the
38-mer was synthesized (59-ATATTTTATAGATAGATA-
GATGGTATCCAAGTCAGAAA-39), end-labeled with
32P,
and equal molar ratios of the 38-mer containing the 5-FU, the
AA ID loop, or unaltered strand and the complementary strand
was mixed, heated to 95uC, and allowed to cool slowly.
Production and purification of the recombinant hMutSa
and hMutSß Protein
Spodoptera frugiperda 9 (Sf9) cells (typically 1.2610
8) were co-
infected with a mixture of hMSH2 and hMSH3 recombinant
baculoviruses constructs (gift of Josef Jiricny, Ph.D. and Giancarlo
Marra, Ph.D.) at a multiplicity of infection of 10. After 72 h, the
cells were collected and total protein extracts were prepared. The
extracts were sedimented at 20,000 g, and the supernatant was
then diluted with buffer A (25 mM HEPES/NaOH, pH 7.6,
1 mM EDTA, 2 mM ß-mercaptoethanol), and loaded onto a 5-ml
Hi-Trap Heparin-Sepharose fast protein liquid chromatography
(FPLC) column (Amersham Pharmacia Biotech, Arlington
Heights, IL). The protein complex was eluted with a 45 ml linear
gradient from 25 to 100% of buffer B (25 mM HEPES/NaOH,
pH 7.6, 1 M NaCl, 1 mM EDTA, 2 mM ß-mercaptoethanol).
The fractions containing the hMutSß heterodimer were deter-
mined by Western blot and pooled, diluted with buffer A to a
conductivity corresponding to 15% salt, and loaded onto a 5-ml
HiTrap Q FPLC column (Amersham Pharmacia Biotech,
Arlington Heights, IL). The fractions containing the pure hMutSß
complex (eluting at around 550 mM NaCl) were pooled and
stored in aliquots at 280uC. We assessed purity of the
recombinant proteins through Coomassie staining (0.1%) of
7.5% PAGE gels electrophoresed with the eluted proteins.
hMutSa was produced and purified as the same manner as
previously reported [20].
Electromobility gel shift assays (EMSA)
EMSAs were performed as described previously [10,20].
Complementary DNA was labeled at their 59 ends by using T4
polynucleotide kinase and [c-
32P] ATP, and this single DNA
strand was annealed to the three synthesized 38-mer strands.
Binding reactions contained the purified hMutSß (100 nM), and
1610
6 cpm of
32P-labeled double-stranded DNA substrates in a
final volume of 10 ml of binding buffer (20 mM HEPES pH 7.6,
1 mM EDTA, 1 mM DTT, and 10% glycerol (v/v), 100 mgo f
poly (dI-dC)). DNA protein complexes were separated under non-
denaturing conditions on a 6% polyacrylamide gel using 16TBE
(89 mM Tris borate, 89 mM boric acid, 2 mM EDTA) as a
running buffer. The gels were then dried, and protein-DNA
complexes were visualized using a phosphorimager (Molecular
Dynamics, Sunnyvale, CA). To determine specificity of binding of
hMutSß to the DNA, 4 mM ATP was added to release the DNA-
protein complexes.
DNA binding analysis (IAsys)
The binding and dissociation characteristics between the MMR
complex and DNA substrates was performed as described
previously [20,28]. We utilized the IAsys biosensor system (Affinity
Sensors, Cambridge, UK) to characterize the hMutSß-DNA
interaction. The IAsys system utilizes surface plasmon resonance
to detect total internal reflectance measurements. We synthesized
a5 9-biotinylated DNA complementary oligomer (see sequence
above) and annealed this to each of the three 38-mers to make
double-strand DNA to bind the IAsys streptavidin-coated SA
sensor chip (IAsys Auto Plus microcuvettes, Affinity Sensors). The
protein heterodimer hMutSß was diluted to 100 nM in running
buffer (0.02 M NaCl, 25 mM Tris-Cl, pH 7.8, 1 mM DTT,
2%glycerol, 0.05% IGEPAL 20 and 10 mM MgCl2) and added to
the chip for monitoring and recording the interaction for
5 minutes. Dissociation studies were performed by adding
dissociation buffer (containing 4 mM ATP) for 5 minutes. Two
washes of 50 ml 3 M NaCl were used to regenerate the binding
surface of the microcuvette after each injection of hMutSß. All
experiments were performed at 25uC. Data were collected and
analyzed using the IAsys evaluation software (IAsys plot version
3.0).
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